Abstract: The present disclosure provides methods for estimating cancer susceptibility, risk of developing multiple tumor sites, and the aggressiveness of prostate cancer. Disclosed are interactions among three polymorphisms: the Acid Phosphatase Locus-1 (ACP1) 228C>T (rs11553742) and 413A>G (Q106R, rs79716074) single nucleotide polymorphisms (SNPs), and a SNP for the Astrocyte Elevated Gene-1 (AEG1) (rs2438211). Additionally interactions among these polymorphisms are disclosed to modify the underlying quantitative expression of major cancer-related genes, indicating that optimization of these gene products by pharmacologic or gene therapy interventions would be beneficial as a cancer therapy to reduce the risk of tumor metastasis, and would also be beneficial in preventing cancer.

Abstract: A deletion mutant associated with CCR5, particularly a CCR5 delta 32 deletion mutant, and its use for predicting the survival rate of patients having multiple sclerosis.

Abstract: The invention relates to methods for diagnosing a person's susceptibility for having an increased risk for the development of breast cancer. The invention relates further to methods for treating persons diagnosed for having increased risk for the development of said disease, in order to prevent the development of said disease.